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Abstract
The in vivo studies of myocardial infarct using c-kit
+/Lin
2 cardiac stem cells (CSCs) are still in the early stage with margin or
no beneficial effects for cardiac function. One of the potential reasons may be related to the absence of fully understanding
the properties of these cells both in vitro and in vivo. In the present study, we aimed to systematically examine how CSCs
adapted to in vitro cell processes and whether there is any cell contamination after long-term culture. Human CSCs were
enzymatically isolated from the atrial appendages of patients. The fixed tissue sections, freshly isolated or cultured CSCs
were then used for identification of c-kit
+/Lin
2 cells, detection of cell contamination, or differentiation of cardiac lineages.
By specific antibody staining, we demonstrated that tissue sections from atrial appendages contained less than 0.036% c-
kit
+/Lin
2 cells. For the first time, we noted that without magnetic activated cell sorting (MACS), the percentages of c-kit
+/
Lin
2 cells gradually increased up to ,40% during continuously culture between passage 2 to 8, but could not exceed .80%
unless c-kit MACS was carried out. The resulting c-kit
+/Lin
2 cells were negative for CD34, CD45, CD133, and Lin markers, but
positive for KDR and CD31 in few patients after c-kit MACS. Lin depletion seemed unnecessary for enrichment of c-kit
+/Lin
2
cell population. Following induced differentiation, c-kit
+/Lin
2 CSCs demonstrated strong differentiation towards
cardiomyocytes but less towards smooth and endothelial cells. We concluded that by using an enzymatic dissociation
method, a large number, or higher percentage, of relative pure human CSCs with stable expression of c-kit
+ could be
obtained from atrial appendage specimens within ,4 weeks following c-kit MACS without Lin depletion. This simple but
cost-effective approach can be used to obtain enough numbers of stably-expressed c-kit
+/Lin
2 cells for clinical trials in
repairing myocardial infarction.
Citation: He J-Q, Vu DM, Hunt G, Chugh A, Bhatnagar A, et al. (2011) Human Cardiac Stem Cells Isolated from Atrial Appendages Stably Express c-kit. PLoS
ONE 6(11): e27719. doi:10.1371/journal.pone.0027719
Editor: Marcello Rota, Brigham & Women’s Hospital - Harvard Medical School, United States of America
Received October 12, 2011; Accepted October 23, 2011; Published November 2 , 2011
Copyright:  2011 He et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants from the National Institutes of Health 5P20RR024489 (to AB/JQH) and 5P01HL078825 (to RB). The funders had no
role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: rbolli@louisville.edu
Introduction
It is a long-held belief that mammalian cardiomyocytes withdraw
from the cell cycle during the perinatal period and that the
mammalian heart is a terminal post-mitotic organ incapable of self-
regeneration after myocardial injury. However, this paradigm has
been challenged by the work of Beltrami and colleagues [1] who for
the first time, discovered specialized cells within the heart tissue
expressing stem cell markers (c-kit, Sca-1, and MDR1). These cells,
termed adult cardiac stem cells (CSCs), are capable of fulfilling the
criteria for stem cells including self-renewal, clonogenicity, and
multipotency. To date, at least 5 different types of CSCs, including
the c-kit
+/Lin
2 cells [1,2]; the Sca-1
+ cells [3,4]; the Isl1
+ cells [5,6],
the cardiac side population (Abcg2
+/MDR
+) [7,8], and cardio-
sphere-derived stem cells (c-kit
+/Sca-1
+/Flk1
+) [9–11], have been
isolated and characterized from hearts bydifferent laboratories [12–
16]. There may be additional CSCs populations [17–19]. Although,
the origin and the function of these cells remain unclear, different
putative adult CSCs most likely represent different developmental
and/orphysiological stages ofa uniqueCSCpopulationintheadult
mammalian heart [20].
The c-kit
+/Lin
2 cells represent one of the major CSC
populations founded in the heart [21]. In both children and
adults, these cells are present in highest number in the right atrial
appendage [22,23]. In vitro, the c-kit
+/Lin
2 CSCs show typical
stem cell properties and pluripotency, and some in vivo studies
have shown that transplantation of these cell improves cardiac
function in animal models of myocardial infarct (MI). However,
the results are variable. Some studies report marked improvement
in function, whereas other report only marginal or non-significant
effects on cardiac structural and/or function [13,24–27]. It is likely
that this variability stems from the lack of understanding of the
biological properties of these cells before and after transplantation
and how these cells could be reproducibly identified, isolated and
transplanted. In particular, issues such as the specificity of c-kit as a
CSC marker, contamination from other cell source, CSC lineage
and the expression of cardiac lineage markers before and after
differentiation remain controversial [16,28–30].
The c-kit antigen is primarily expressed in hematopoietic stem
cells, but its expression disappears in cells of hematopoietic lineage
after differentiation, except for mast cells [31–33]. Therefore, it
has been recently suggested that c-kit
+ cardiac progenitor cells
isolated from human heart tissue are actually mast cells [34].
Similarly, it is unclear whether or not the c-kit population is
contaminated by other cells such as the cardiac fibroblasts, mast
cells or hematopoietic lineage cells and whether the expression of
c-kit remains stable after tissue processing and long-term cell
culture. Data on the expression of lineage markers are even more
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8conflicted. For instance, Anversa and colleagues reported that
human c-kit
+ cells (both cloned and uncloned CSCs), do not
express all the cardiac lineage markers such as GATA4, Nkx2.5,
MEF2c, a-sarcomeric actin (a-SA), a-smooth muscle actin (a-
SMA), CD31, and KDR before differentiation as measured by
flow cytometry; whereas 4–23% of the un-fractional cell
population at P0 was found to be positive for these markers
[12,35,36]. In their recent study, they reported a similar lack of
expression of cardiac lineage markers, except for KDR, which was
found to be expressed in ,3% of c-kit
+ population [36]. In
contrast, Itzhaki-Alfia et al have reported that the un-fractioned
adult human CSCs are positive for GATA4
+ (60%) and cardiac a-
SA
+ (60%) even before c-kit purification [22]. In neonatal hearts
and heart tissue from young children, however, the percentages of
c-kit
+ ranged from 5%–9% and only small percentage (1% to 3%)
of c-kit
+ cells were double positive for Nkx2.5
+ [23]. Clearly, many
aspects about these cells remain to be fully understood. Therefore,
the present study was designed to systematically characterize the c-
kit
+/Lin
2 CSCs isolated from adult human heart samples. We
examined CSC markers adapted to post-isolation, expansion,
purification, Lin depletion (Lin-dep); their vitro differentiation
properties, and potential contamination by other cell types, such as
cardiac fibroblasts and mast cells. The overall goal in this work was
to provide essential but practical information required for
optimizing the use of human CSCs for future clinical trials in
MI repair.
Materials and Methods
Tissue samples of discarded atrial appendages from patients
were randomly divided into 4 groups (Figure 1). Group 1
comprised of tissue sections for immunohistochemistry (IHC) to
identify c-kit
+ cell and cardiac a-SA or freshly isolated cells directly
used for immunocytochemistry (ICC) with human c-kit specific
antibody. Group 2 cells were continuously cultured at 37uCu pt o
passage 10 (P10), but without any purification or enrichment steps
using c-kit or Lineage (Lin) magnetic activated cell sorting
(MACS). Group 3 cells were subjected to c-kit MACS and/or
Lin-dep. In the last group, isolated cells went through single or
double MACS procedures with c-kit and Lin antibodies and these
cells were then used for cardiac differentiation. All isolated cells
were passed every 4–5 days up to P10. The cells were collected on
every other passage for ICC and flow cytometry using various
antibodies anti c-kit, hematopoietic Lin markers, KDR, CD31,
CD34, CD45, CD133, and cardiac lineage markers (such as
Nkx2.5 and GATA4).
Human atrial appendages
A total 30 atrial appendages specimens were collected from 30
patients during the routine procedure of open heart surgery from
Jewish Hospital at University of Louisville. The specimens were
from right atrial appendages and the size of samples varied from
50 to 500 mg. No information was able to be collected in terms of
patients’ age, sex, types of cardiac diseases, and properties of non-
cardiac diseases, and other medical history of patients based on the
approved protocol. A written consent agreement was obtained for
collection of discarded atrial appendages according to a protocol
approved by the Institutional Review Boards on human subject
research at University of Louisville.
Cell dissociation and culture
Enzymatic digestion was used to dissociate human CSCs from
atrial appendages as described previously [12]. Briefly, after remov-
ing fat, the tissues were washed 36with cold Ca
2+/Mg
2+-free PBS
buffer. Thereafter, the samples were minced into small pieces
(,1 mm) and washed extensively in fresh cold PBS buffer. The
chopped tissueswerethen transferred into 50 mltube and incubated
with collagenase II (30 U/ml) in 37uC shaker for 60 min. The
loosened tissues were further mechanically dissociated by gently
pipetting. The undigested tissue clumps were allowed to settle down
by gravity on ice for 10 min followed by transferring the supernatant
into another 15 ml tube. After centrifuge at 1,400 rpm for 5 min,
the cell pellet was resuspended in fresh CSC culture medium
consisting of Ham’s F12 (Invitrogen, CA), 10% FBS (Hyclone, UT),
10 ng/ml human bFGF (PeproTech, NJ), 0.2 mM L-glutathione,
and 0.005 U/ml human erythropoietin (both from Sigma, MO).
The cells suspension was then plated in culture flask and cultured in
37uC incubator supplied with 95% air/5% CO2.N e x td a y ,t h e
medium was entirely changed to remove all dead cells and cell
debris. The adherent cells were continuously cultured with medium
change every other day or split at 4–5 days with TrypLE Express
(Invitrogen, CA). The subsequent analyses were done on the entire
un-fractional population of cultured cells or after c-kit MACS and/
or Lin-dep.
Figure 1. Experimental design. The samples of human atrial
appendages (AA) were randomly sorted in 4 groups and used either
for immunohistochemistry (IHC) or enzymatically dissociated into single
cells for Immunocytochemistry (ICC) or Flow Cytometry (Flow). The
cultured cells were then underwent c-kit magnetic activated cell sorting
(MACS) and/or followed by Lineage depletion (Lin-dep.) or simply kept
culturing without any purification and selection. The resulting c-kit
+/
Lin
2 cardiac stem cells (CSCs) were used for cardiac differentiation and
analyzed by Flow, ICC and RT-PCR.
doi:10.1371/journal.pone.0027719.g001
Human Cardiac Stem Cells Stably Express c-kit
PLoS ONE | www.plosone.org 2 November 2011 | Volume 6 | Issue 11 | e27719Magnetic activated cells sorting (MACS)
The c-kit
+/Lin
2 CSCs were enriched using the c-kit MACS kit
according to the manufacturer’s instructions (Miltenyi Biotec,
Germany). Briefly, total populations of adherent cells between P1
to P3 (dependent on cell density) were enzymatically dissociated
into single cell suspension. The cells were collected and incubated
with microbeads directly conjugated to mouse monoclonal anti-
human c-kit antibody (clone AC126) at 4uCt o8 uC for 20 min.
The cells were then loaded into a MACS column which was
placed in the magnetic field of MACS Separator (Miltenyi Biotec,
Germany). The labeled c-kit
+ cells were retained on the column
and unlabeled cells were eluted. After column was removed from
magnetic field, the magnetically retained c-kit
+ cells were collected
as positively selected cell fraction for further expansion and
analysis with ICC, flow cytometry, and/or RT-PCR.
To exclude the potential contamination of Lin
+ cells (such as T
cells, B cells, NK cells, dendritic cells, monocytes, granulocytes,
erythroid cells, and their committed precursors), a Lineage Cell
Depletion Kit (Miltenyi Biotec, Germany) was used to purify c-kit
+
cell populations. This kit is a biotin conjugated-monoclonal
antibody cocktail consisting of CD2, CD3, CD11b, CD14,
CD15, CD16, CD19, CD56, CD123 and CD235a antibodies.
Similar to c-kit MACS, Lin-depletion required the cells to be
incubated with the antibody cocktail at 4uCt o8 uC for 15 min and
then incubated with microbeads conjugated anti-biotin secondary
antibody for another 15 min. The magnetically labeled Lin
+ cells
were depleted by retaining them on MACS column in magnetic
field while unlabeled Lin
2 cells passed through the column and
were collected for further expansion and/or analysis.
Flow Cytometry
Flow Cytometry was used to analyze the expression patterns of
CSCs markers during cell culture. Briefly, after detaching
adherent cells with TrypLE Express (Invitrogen), single cell
suspension was filtered through 70 mm nylon mesh and then
centrifuged and washed with 265 ml PBS (Invitrogen). Cells were
incubated on ice for 30 to 60 min (depending on individual
antibody) with appropriate combination of fluorochrome conju-
gated-primary and/or secondary antibodies. The labeled cells
were then washed 36 with PBS, fixed with 1% PFA for 10 min
and resuspended in FACS buffer for flow analysis on LSRII Flow
Cytometer (BD Bioscience) using FacsDave 6.0 software (BD
Bioscience, CA) or FlowJo 7.5 (TreeStar, Ashland, USA). The
following antibodies and dilutions used in Flow Cytometry and
ICC (see below) included: (1) Unconjugated primary antibodies:
rabbit IgG anti-c-kit; mouse IgG anti-GATA4 (both from Santa
Cruz, CA); mouse IgG anti-Nkx2.5; mouse IgG anti-Fibroblast
(both from Abcam, MA); mouse IgG anti-Tryptase (Chemicon,
CA); mouse IgM anti-Cardiac a-SA; mouse IgG anti-a-SMA;
rabbit IgG anti-KDR (all from Sigma, MO). (2). Fluorochrome
directly conjugated primary antibodies: mouse IgG anti-CD31-
APC; mouse IgG anti CD34-APC; mouse IgG anti CD45-APC;
mouse IgG anti CD133-APC (all from eBioscience, CA); mouse
IgG anti-Lin cocktail (CD2, CD3, CD14, CD16, CD19, CD24,
CD56, CD68, CD123, CD235a-FITC (BD Bioscience, CA); (3).
Secondary antibodies: donkey anti-rabbit IgG-FITC; donkey anti-
mouse IgG-FITC (both from Invitrogen, OR); donkey anti-mouse
IgM-TRITC (Jackson Immunoresearch, PA).
Immunocytochemistry (ICC) and immunohistochemistry
(IHC)
The expression of CSC markers were also analyzed by immuno-
fluorescence techniques. Briefly, freshly isolated or detached cell
suspension was subjected to live-cell staining or fixation with 4%
PFA before primary antibody incubation, depending on the location
of antigen, i.e., an intra- or extra-cellular marker. Live-cells were
incubated on ice with the primary antibody for 30–60 min and
fixed-cells were incubated at room temperature for 20–45 min
depending on individual antibody. In each case, PBS supplemented
with 10% horse serum was used as blocking solution. The sample
was incubated with an appropriate combination of fluorochrome
conjugated and/or primary and secondary antibodies (see Flow
Cytometry above). Cells were stained by DAPI (or Hoechst 33342
for live-cell) for identifying the nuclei. Samples were then centrifuged
in Cytospin. Images were collected and analyzed using a LSM 510
META Confocal laser-scanning microscope and/or an Axiovision
Fluorescence microscope (both Carl Zeiss, Germany). The percent-
age of positive cells of interest was estimated on the basis of total
nuclei (,300 to 600/per data set) counted from each sample slide of
at least three patients.
IHC was used to determine the percentages of c-kit
+ in tissue
sections. Briefly, the fat was removed from atrial samples, and
followed by washing 36 in cold PBS buffer to remove possible
blood, and tissues were then fixed in 10% formalin solution for
24 h followed by 70% ethanol for another day at room
temperature. The fixed tissue blocks were then embedded in
paraffin and sectioned at a thickness of 4 mm. Negative controls
were included each time by omitting primary antibody with a
normal procedure. Following counter-staining with DAPI, slides
were mounted with fluorescence anti-fade Vectashield mount-
ing medium under cover slip. LSM 510 META Confocal and/
or Axiovision fluorescence microscopes were used to acquire
fluorescent images and percentage of c-kit
+ was estimated based
on total nuclei (,3000) counted from three sections of each
sample among at least three patients. The primary antibodies
used were rabbit IgG anti-c-kit (Dako, CA) and mouse IgM
anti-Cardiac a-SA (Sigma, MO); the secondary antibodies
included donkey anti-rabbit IgG-FITC (Invitrogen, CA) and
donkey anti-mouse IgM-TRITC (Jackson ImmunoResearch,
PA).
RT-PCR
Total RNA was extracted from cells using the PARIS Kit
(Applied Biosystem, CA), and then treated with DNase to eliminate
DNA contamination. The quality and quantity of total RNA was
estimated with Nanodrop 2000c (Thermo Scientific, DE). RT-PCR
was run with Qiagen Onestep RT-PCR kit according to
manufacturer’s instructions. For each measurement, 100 ng of
total RNA was used as a template and RT-PCR was performed
using primers (from IDT, Coralville, IA) listed below at concentra-
tion of 0.5 mM. Cycle conditions were: 50uC/30 min, 94uC/
15 min, 94uC/30 s for denature, 58–60uC/30 s for annealing, and
72uC/30 s for extension with total cycles of 35. PCR products were
run on 2% agarose/16TBE gel stained with ethidium bromide for
30 min (Bio-Rad, CA). The following primers were used: c-kit:
forward-TACTGAT TCACTGCATGGCTCCCA; reverse-ACA-
GAGTGCCTTAAGTGCAGGTGA. GATA4: forward -CGAATG-
ACGGCATCTGTTTGCCAT; reverse-GCAGAACAGCAATGT-
GCAGAGGA. ME F2c:forward-TGGCTGCATGTTTGAATCA-
GGTGG;reverse-AGACCACCTGTGTTACCTGCACTT.KDR:
forward-AGAGGCTTTGTTTAGGACGTGGGT; reverse-TTG-
AACCTCCCGCA TTCAGTCTCA. vWF:f o r w a r d - A C T C A G T -
GCATTGGTGAGGATGGA; reverse-TCGGACAC ACTCAT-
TGATGAGGCA. Cardiac troponin I (cTnI): forward-AATCAGAC-
GCCGCTCCTC CAAC; reverse-TCTCCCACCTCCCGGTT-
TTCCTTC. MLC2v: forward-AGAGCTGGGCGGA GTGTG-
GAAT; reverse-TTTCACGTTCACTCGCCCAAGGG. GAPDH:
Human Cardiac Stem Cells Stably Express c-kit
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GATGGCATGGACTGTGGTCAT.
In vitro differentiation
In vitro assays of cardiac differentiation were performed to
examine three cardiac lineages, cardiomyocytes, smooth muscle,
and endothelial cells, according to the modified method from
previous published studies [22,37]. Briefly, c-kit
+/Lin
2 CSCs were
seeded in triplicates in either 6-well plates (for RT-PCR analysis)
or T75 flasks (for ICC assay) and cultured for 1 to 2 days in human
CSC medium. To induce cardiac differentiation, the culture
medium was switched into differentiated medium consisting of
DMEM (Invitrogen, CA), 10% FBS (Hyclone, NJ), and 10 mM5 -
azacytidine (5-AZ, Sigma, MO) for 3 days. Cells were continu-
ously cultured up to 35 days and the medium was changed every
other day. Total RNA extracted from control (Day 0) and
differentiated cells (Day 3, 7, 14, 21, 28 and 35) and used to
analyze gene expression patterns of cardiac lineages (c-kit,
GATA4, MEF2c, KDR, vWF, cTnI, and MLC2v) by RT-PCR
with specific primers purchased from IDT (see above). Protein
expressions was examined only on Day 0 before differentiation
and Day 35 after differentiation by ICC using cardiac lineage-
specific antibodies: rabbit IgG anti c-kit (Santa Cruz, CA), mouse
IgG anti-CD31-APC (eBioscience, CA), mouse IgG anti-a-SMA,
mouse IgM anti-cardiac a-SA (both from Sigma, MO), and rabbit
IgG anti-cTnI (Chemicon, CA). The secondary antibodies
consisted of: donkey anti-rabbit IgG-FITC; donkey anti-mouse
IgM-TRITC or FITC (c-kit) or (a-SMA or a-SA) (all from
Invitrogen, CA).
Other materials
Human umbilical vein endothelial cells (HUVECs, CRL-1730),
human fibroblasts (CRL-110), and human Jurkat cells (TIB-152)
were obtained from ATCC (Manassas, VA). Human bone marrow
cells were purchased from AllCells (Emeryville, CA). Total RNA
of human carotid artery was bought from Agilent Technologies
(Santa Clara, CA). Cells were grown according to manufacturer’s
product instructions. All chemicals used were from Sigma (MO)
and medium from Invitrogen (CA), unless otherwise stated.
Statistical analysis
The data are presented as mean 6 SEM (standard error of
mean). Student’s t test with two-tailed distributions was used to
compare two groups. One-way ANOVA followed by Bonferroni
test was used to compare three and more groups. p,0.05 was
considered significantly. Cells from at least 3 patients were used for
each group.
Results
c-kit expression pattern in CSCs before and after c-kit
MACS
To ensure high quality and purity of the cells for future clinical
trials, changes in c-kit expression were examined after isolation
and/or long-term culture of human CSCs. As shown in Figure 2,
c-kit
+ cells were readily identified in section of the atrial
appendages, however, only a small percentage (,0.036%) of cells
(counted by nuclear staining) in the atria displayed c-kit positivity
(Figure 2A.a). Estimates of the percentage of c-kit
+ cells in freshly-
dissociated single cell population from atrial appendage indicated
Figure 2. C-kit
+ cells before purification. Panel A showed the representative images on tissue section (a) of atrial appendages or freshly isolated
cells before (b) and after plating (c–f) at passage 2 (P2) to P8 from the same patient. C-kit
+ cells were showed in green (FITC, see arrows in a and b, but
all green cells in c–f) and nuclei were stained in blue (DAPI). The negative controls included secondary antibody (g. 2
ndAB) alone and human Jurkat
cells (h) stained with c-kit antibody. Scale bars=20 mm. Panel B displayed the Mean6SEM data from ICC (open bar) and Flow Cytometry (filled bar).
n=4–9 patients. *p,0.05, ***: p,0.01, ns: no significance, all were compared to control (Tissue).
doi:10.1371/journal.pone.0027719.g002
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+ as measured by ICC
(Figure 2A.b and 2B). The larger number of c-kit
+ cells obtained in
dissociated cells (p,0.05, n=4 patients) may be due to more
accurate measurement of the entire cell population than those with
tissue sections. However, because of a large number of dead cells,
cell debris and undissociated cells in the isolate, this estimate could
potentially also result in an overestimation of c-kit
+ cells.
Nevertheless, both the techniques indicated that the abundance
of c-kit
+ cells in the atrial appendage is quite low.
To evaluate the stability of c-kit expression during long-term
culture, we collected cells after every other passage to examine
changes in c-kit expression by ICC and flow cytometry, separately.
We noted that the percentages of c-kit
+ cells were gradually
increased from 3.660.82% in freshly isolated cells up to ,40%
between P2 to P8 before c-kit magnetic selection and purification
(Figure 2). The average percentages of c-kit
+ cells from P2 to P8 was
significantly higher than tissues section and freshly isolated cells
(p,0.01, n=4 to 9 patients, Figure 2B). Because mature
lymphocytes do not express c-kit [38], we used a cloned human
Jurkat cell line (T lymphocyte) and 2
nd antibody as negative controls
to exclude potential false positive. Our data showed that both
control groups produced no c-kit
+ staining (Figure 2A.g and h).
To purify and enrich c-kit
+ CSCs, cultured cells were
enzymatically detached at passage 1 to 2 and c-kit MACS was
performed through column with un-fractional single cell popula-
tion after incubation with human c-kit antibody-conjugated
magnetic beads (see Materials and Methods). As shown in
Figure 3, the percentage of c-kit
+ cells in the population increased
dramatically up to ,80%, as analyzed by flow cytometry
(Figure 3A, upper row) and ICC (Figure 3A, lower row). On
average, 79.163.2% and 87.2%62.1% cells were identified to be
c-kit
+ by ICC and flow cytometry, respectively, between passage 2
and 10 (n=3). There was no statistically significant difference
between these passages, indicating that the c-kit expression was
quite stable during long-term culture for up to 10 passages for a
total of 40 to 50 days. In addition, karyotyping analysis of sorted
CSCs was normal both at lower (P3) and high (P10) passages with
46 XY or YY based on total 60 cells from three patient samples
(data not shown). Moreover, c-kit
+ cells demonstrated the typical
stem cell property of clonogenesis (data no shown). Collectively,
these data indicate that the percentage of c-kit
+ cells in intact heart
section of atrial appendages is much lower than in freshly isolated
cells and continuous culture of un-fractionated cells without any
purification for c-kit. The population could be further enriched by
c-kit MACS and that once isolated these cells stably express the c-
kit antigen.
Expression of hematopoietic markers in CSCs
Having established the abundance and the stability of c-kit
+ cells
in culture, we next examined whether the c-kit
+ population isolated
from the atrial appendage was contaminated by hematopoietic stem
cells (which also express c-kit) or cells of hematopoietic lineage
Figure 3. C-kit
+ cells after purification. Panel A showed the representative data of Flow Cytometry (upper row), where c-kit-FITC was shown on
x-axis, cell Events# was on y-axis, and the percentages of c-kit
+ cells was in red histograms. The representative images of ICC from the same patient
was displayed in middle row, where c-kit
+ cells were showed in green (FITC) and nuclei were stained in blue (DAPI) at P2-P10 after c-kit MACS but
without Lin-dep. Scale bar=20 mm. Panel B displayed the Mean6SEM data from ICC (open bar) and Flow Cytometry (filled bar). The percentages of c-
kit
+ cells by ICC and Flow showed no statistical significant difference (ns) compared to P2. n=3 patients.
doi:10.1371/journal.pone.0027719.g003
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hematopoietic cells. In addition to c-kit (CD117) hematopoietic
stem cells express other hematopoietic markers, including CD31,
CD34, CD38, CD45, CD59, CD90, CD105, CD106, CD133,
CD164, CD184, CD201, and CD202 [39]. However, the mature
hematopoietic cells (T/B lymphocytes, monocytes, granulocytes,
and NK cells) express Lin markers, such as CD2, CD3, CD4, CD5,
CD8, CD11b, CD13, CD14, CD16, CD18, CD19, CD20, CD24,
CD33, CD56, CD61, CD66, CD71, CD 235, and Ter119 [39].
Therefore, to identify contaminating cells we measured these
markers in the c-kit
+ cell population.
We found that without any selection procedures, freshly isolated
cells from the atrial appendage contained ,10% of Lin
+ cells
(Figure 4A.a, e, I and 4B) as identified by ICC using a mixed Lin
antibody cocktail consisting of CD2, CD3, CD14, CD16, CD19,
CD20 and CD56. To exclude the possible contamination from
hematopoietic stem cells the following three sets of experiments
(n=3 patients for each set) were performed in various combina-
tion of c-kit MACS and Lin-dep showed in Figure 4: (a) Freshly
isolated cells were subjected to c-kit MACS followed by Lin-dep
between P1 to P2 (top row). After a two-step MACS procedure,
barely any Lin
+ cells were seen (Figure 4A.c, d and 4B); (b) Freshly
isolated cells were subjected to c-kit MACS, but no Lin-dep, in
which Lin
+ cells disappeared afterwards (middle row, Figure 4A.g.,
f, 4B); (c) Freshly isolated cells were continuously cultured without
c-kit MACS and Lin-dep, where Lin+ cells also disappeared
(bottom row, Figure 4A.k, l and 4B). In all three groups, the
average percentage of Lin
+ cells was 12.360.9% in freshly isolated
cells (n=3 patients), however, these cells were undetectable after
one or two passages whether or not Lin-dep step was applied.
However, the percentages of c-kit
+ cells remained high with or
without Lin-dep (data not shown), similar to the levels shown in
Figure 2.
To confirm these results, the cells were treated with c-kit (-
FITC) v.s. Lin (-APC) specific antibodies, and antibody binding
was detected by flow cytometry. As showed in Figure 4C and 4D,
Lin
+ cells were not detectable after c-kit MACS whether or not
Lin-dep was used. Although the percentages of c-kit
+/Lin
2 cells
were slightly reduced after c-kit MACS, from 79.563.1% (before
Lin) to 65.6610.8%, the difference did not reach statistical
significance (Figure 4D, ns, n=3 patients). In control experiments
with human bone marrow cells using two different measurements
(ICC vs Flow), we obtained comparable percentages of Lin
+ cells
264.762.0% by ICC (Figure 4B) vs 50.564.4% by flow
cytometry (Figure 4D). A small population 13.462.5% of cells
was c-kit
+ (Figure 4D; n=3 in each group).
To assess contamination by hematopoietic stem cells, the
expression of hematopoietic stem cells markers (CD34, CD45 and
CD133) was analyzed in the c-kit
+ cell population. Although the
percentages of c-kit
+ cells remained high at 74.364.3% and
68.5613.3% (CD34), at 74.864.8% and 71.4613.5% (CD45),
and at 85.665.6% and 61.6614.2% (CD133) before and after
Lin-dep (n=3 patients in each group), respectively, there was no
detectable signals of CD34
+, CD45
+ and CD133
+ cells in c-kit
+
cells whether or not Lin-dep was used (Figure 5). Using human
bone marrow cells as positive control, we found that 20.366.6%
(ranging from 1160.85% in CD45, 23.761.6% in CD133, to
26.1610.4% in CD34 group, respectively) were c-kit
+, whereas
the abundance of CD34
+ cells was 4.561.8%, CD45
+ cells was
45.9610.5%, and CD133
+ cells was 0.560.2% (Figure 5B, 5C,
and 5D, n=3 patients). Collectively, these data indicate that
single-step purification by c-kit MACS is sufficient to produce a
highly enriched c-kit cell population and that the inclusion of an
additional step of Lin-dep does not lead to an increase in the
percentage of c-kit
+ cells in long-term culture up to 10 passages.
The resultant c-kit
+ cell population did not express Lin markers or
typical hematopoietic stem cell markers (like CD34, CD45, or
CD133), indicating that cell population after c-kit MACS is not
contaminated by hematopoietic stem cells or mature leukocytes of
hematopoietic origin.
Contamination by fibroblasts and mast cells
Previous studies have shown that cardiac fibroblasts represent a
heterogeneous population in the heart with regard to their
phenotype, specific functions, and cellular origins [40]. To exclude
the possibility that isolated cells from atrial appendages are
fibroblasts or contaminated with fibroblasts, we measured the
abundance of fibroblasts in the c-kit
+ cell population using a
fibroblast-specific antibody raised against ‘‘Fibroblast Surface
Protein’’ (FSP) [41–44]. We found that a small proportion of
un-fractional cells isolated from atrial appendages were fibroblast
positive cells (22.760.9%, n=3 patients); however, these fibro-
blasts were entirely removed by c-kit MACS procedure (Figure 6).
As a positive control, we examined human fibroblasts, which
showed that 93.361.2% of the population was FSP
+, whereas a
negative control using 2
nd antibody failed to generate a positive
signal for fibroblasts (Figure 6).
Although the c-kit antigen has been widely used to identify
stems cells in the heart [13], this antigen is also expressed by
cardiac mast cells [45]. Thus, in principle, it is possible that some
of the stem cell recognized in the heart may be mast cells. To
exclude this possibility, we used a well-documented mast cell-
specific antibody, Tryptase [23,33,34,46] to examine mast cell
contamination in the sorted c-kit
+ cell population. However, as
shown in Figure 7, we did not observe any tryptase
+ mast cells in c-
kit
+ cells isolated from three different patients (n=3). In contrast, a
small percentage (0.9560.3%, n=3) of human bone marrow cells
displayed positive staining by the mast cell antibody (Figure 7).
These data clearly showed that the c-kit
+ cell population isolated
from atrial appendages was not contaminated by fibroblast and c-
kit reactivity of these cells could not be attributed to the presence
of cardiac mast cells.
Cardiac lineage differentiation
The CSCs are believed to be the pre-committed cardiac-
resident stem or progenitor cells and therefore, they should carry
typical stem cell and/or cardiac markers (like c-kit and GATA4
etc). These cells also have the capability to differentiate into three
cardiac lineages both in vitro and in vivo under certain condition.
Therefore, we examined changes in markers of cardiomyocytes
(MEF2C, GATA4, Nkx2.5, a-SA, cTnI, and MLC2v), smooth
muscle cells (a-SMA), and endothelial markers (CD31, KDR, and
vWF) before and after differentiation of the c-kit
+ cell population.
Before induced differentiation, the unsorted cell population from a
majority of patients contained 1762.5% CD31
+ cells as measured
by ICC (Figure 8A.a, and 8B, n=5 patients) and 21.762.6%
CD31
+ cells as measured by flow cytometry (n=3 patients,
data not shown). These ‘‘contaminating’’ CD31
+ cells could be
removed by c-kit MACS (Figure 8A.b). However in two cases (2
out of 7; Figure 8A.c and d, n=2), unsorted cells demonstrated
similar percentages (15% and 21%) of CD31
+ cells before c-kit
MACS, but interestingly, but 18–20% CD31
+ cells were still
present after c-kit MACS (data not shown), indicating a unique
subtype of c-kit
+/CD31
+ among c-kit
+ cell population. Moreover,
in a majority of patients (5 out of 7) 11.761.2% of the cells
identified by ICC and 19.161.2% of the cells identified by flow
cytometry (n=3 patients, data not shown) were KDR
+ before c-kit
MACS (Figure 8C.f. and 8D, n=5 patients). Like the CD31
+ cells,
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PLoS ONE | www.plosone.org 6 November 2011 | Volume 6 | Issue 11 | e27719Figure 4. Lineage positive (Lin
+) cells. Panel A showed the representative Confocal images of Lin
+ antibody staining (red-APC) on freshly isolated
cells as well as plated cells at P0, P6, and P10 with (+) and/or without (2) c-kit MACS and/or Lin-dep (Panel A, top row-with c-kit and Lin-dep; middle
row with c-kit, but without Lin-dep; and bottom row without c-kit and Lin-dep). Cell nuclei were stained in blue-DAPI, and Scale bars=20 mm. MACS
were able to be performed at P1 to P2. Human bone marrow (m to o) was used as a positive control for Lin markers (red-APC). Panel B showed the
Mean6SEM data from ICC. ***: p,0.001 (P0, P6, P10 and human bone marrow) compared with control group (Fresh isolated cells). Panel C displayed
the representative data of Flow Cytometry with double staining of c-kit-FITC (x-axis) and Lin-APC (y-axis) in CSCs before (upper) and after (middle) Lin-
dep. Human bone marrow was used as positive control (lower). Panel D showed the Mean6SEM) data of Flow Cytometry from three patients.
***: p,0.001 and ns: no significance; both were compared with control level (Before Lin-dep).
doi:10.1371/journal.pone.0027719.g004
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+ cells could also be removed by c-kit MACS (Figure 8C.f
and g). However, in two patients, the KDR
+ cells in c-kit
+
population were not able to be removed before (13% and 17%,
also see Figure 8C.h) or after (18% and 16%, also see Figure 8C.i)
c-kit MACS, indicating the presence of a c-kit
+/KDR
+ sub-
population of cells (Figure 8C. h and i). Dual staining of c-kit
+ cells
with CD31 and KDR antibodies indicated that they co-express
these antigens in various combination, suggesting existence of c-
kit
+, c-kit
+/CD31
+/KDR
+, or CD31
+/KDR
+ (data not shown).
When HUVECs were used as a positive control, we observed high
percentages of CD31
+ (96.760.7% by ICC and 97.360.7% by
flow, Figure 8B) as well as KDR
+ cells (69.364.1% by ICC and
68.362.0% by flow; Figure 8D) in the cell population. From these
data we conclude that the c-kit
+ cells contain a distinct population
of CD31
+/KDR
+ cells. Because these cells were observed in only a
sub-set of patients, their presence in the heart may be related to
the medical history of these patients, their disease condition or
other clinical factors. However, for now, their potential role
remains unclear.
Although the sorted c-kit
+ cells expressed several early cardiac-
specific transcription factors (GATA4 & Nkx2.5, Figure 9), the
expression of late cardiac lineage markers (a-SA, cTnI, MLC2v,
VWF, CD31, & a-SMA) was low or undetectable both at gene and
protein levels (Figure 10). Specifically, RT-PCR data clearly
showed specific bands for GATA4 & MEF2c in c-kit
+ cells, but no
expression of late cardiac genes (cTnI and MLC2v) was observed
(Figure 10). By ICC analysis, we confirmed that .80% of sorted c-
kit
+ cell population expressed c-kit
+ antigen (also see Figure 3),
among which there were about 4763.5% GATA4
+, 24.361.5%
Nkx2.5
+, 9.3%62.2% a-SA
+, 4.160.4% a-SMA
+ cells. No cTnI
+
cells were detected (Figure 9 and Figure 10, n=3 patients for each
group). We found that the GATA4
+ or Nkx2.5
+ cells were always
c-kit positive, but c-kit
+ cells were not always GATA4
+/Nkx2.5
+
positive (Figure 9).
Measurements of a-SMA by ICC demonstrated low levels of
expression (4.160.4%, n=3 patients) in c-kit
+ populations before
differentiation (Figure 10). The low abundance of this antigen may
Figure 5. Expression of hematopoietic markers. Panel A displayed the representative data of Flow Cytometry with double staining of c-kit-FITC
(x-axis) vs CD34, CD45, or CD133 (all-APC in y-axis) in c-kit
+ cell population before (top row) and after (middle row) Lin-dep. Human bone marrow
(bottom row) was used as positive control. Panel B, C, and D represent the Mean6SEM data of CD34, CD45, and CD133, respectively. Human bone
marrow cells were used as positive control in each group. *: p,0.05, **: p,:0.01, ***: p,0.001; ns: no significance. Each data was compared with the
corresponding control levels (Before Lin-dep.).
doi:10.1371/journal.pone.0027719.g005
Figure 6. Fibroblast specific antibody staining. Panel A showed
the representative images of fibroblast antibody (Fibroblast Surface
Protein in red-APC) staining on human CSCs before (a) and after (b) c-kit
MACS. The 2
nd antibody-APC (c, 2
nd AB only) and human fibroblast cell
line (d) were used as positive and negative controls, respectively. Cell
nuclei were stained in blue (DAPI). Scale bars=20 mm. Panel B showed
the Mean6SEM data of ICC staining from three patients (n=3 patients).
***: p,0.001 compared with control (Before c-kit MACS).
doi:10.1371/journal.pone.0027719.g006
Figure 7. Mast cell specific antibody staining. Panel A demon-
strated the representative Confocal images of mast cell specific
antibody staining (Tryptase, red-APC) on c-kit
+ CSCs (a). Human bone
marrow (b) was used as positive control; the inset in b was an enlarged
image of a mast positive cell. Nuclei were stained in blue (DAPI). Scale
bars=20 mm. Panel B showed the Mean6SEM of ICC data from three
patients (n=3 patients). **: p,0.001 compared to human CSCs.
doi:10.1371/journal.pone.0027719.g007
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+/a-SMA
+) found in tissue
section of the human heart [12]. No positive staining was found
when the secondary antibody alone was used as a negative control
(data not shown). The presence of a-SMA
+ cells in c-kit
+/Lin
2
CSCs suggests that some of these cells are pre-committed to a
cardiac lineage in situ before ex vivo differentiation.
To induce cardiac differentiation, c-kit
+/Lin
2 CSCs were
treated with 10 mM 5-azacytidine (5-AZ) for three days [22,37].
Total RNA was extracted for RT-PCR analysis before (Day 0) and
after differentiation on Day 3, 7, 14, 21, 28 and 35. As shown in
Figure 10A, c-kit (stem cell marker), GATA4, MEF2C (both are
cardiac markers) and KDR (endothelial marker) mRNA were
expressed both before and after differentiation. However, after
differentiation, the expression of vWF (endothelia marker), cTnI
and MLC2v (late cardiac markers) was gradually increased. The
mRNAs appeared on Day 7 and were continuously increased
thereafter. No significant differences were observed in the levels of
these mRNA between Day 28 and Day 35. In these experiments,
total RNA extracted from human heart (H) and human carotid
artery (A) was used as positive control, whereas Jurkat cells (J) were
used as negative control (Figure 10). No detectable signal was
observed with Jurkat cells (J), although all cardiac lineage markers
and endothelial markers were robustly detected in samples from
the heart (H) and artery (A), suggesting true expression of the genes
of interest. To further examine expression levels of cardiac
proteins following differentiation, we performed ICC using cardiac
lineage-specific antibodies anti-CD31, a-SMA, a-SA, and cTnI.
As it shown in Figure 10B and 10C, .85% CSCs expressed c-kit
antigen before differentiation, however, the c-kit signal disap-
peared on Day 35 after differentiation although c-kit mRNA could
still be detected (Figure 10A). In contrast, in we did not find
CD31
+ (endothelial marker) and cTnI
+ (cardiac marker) cells in
the c-kit
+ population before differentiation by ICC, but a small
percentage of a-SMA
+ (4.160.4%) and cardiac a-SA
+ (9.362.0%)
was detected (Figure 10, n=3 patients). Following cardiac
differentiation, these markers were dramatically increased on
Day 35. The CD31
+ cells increased from 0 to 10.361.2%, a-
SMA
+ cells from 4.160.4% to 16.763.5%, a-SA
+ cells from
9.362.0% to 70.766.2%, and cTnI
+ cells from 0% to 71.466.9%
(n=3 patients in each group, p,0.05 or p,0.001, Figure 10).
These data suggest that the pre-committed c-kit
+/Lin
2 CSCs are
capable of differentiating into three cardiac lineages after
induction by 5-AZ. Although a majority of the c-kit
+ (about
70%) tend to become cardiomyocytes, some cells (about 30%)
differentiate into smooth muscle and endothelial cells.
Discussion
The results of the current study show that both tissue sections and
cells freshly isolated from human atrial appendages specimens
contain a small population of c-kit
+/Lin
2 cells. Without further
purification, a gradual increase in the percentage of c-kit
+ cells was
observed, which increased to 40%. The percentage of c-kit
+ cells did
not increase further upon Lin-depletion following c-kit MACS.
Figure 8. Endothelial specific antibody staining. Panel A showed the representative images of CD31 antibody staining before (a and c) and
after (b and d) c-kit MACS in two different subtypes of cell populations in patients. Majority patients (Group 1) did not displayed CD31
+ cells after c-kit
MACS (a and b), but few patients (Group 2, n=2) still demonstrated the reproduced CD31
+ cells after c-kit MACS (c and d). In all images, CD31
+ cells
were labeled in red (APC) and nuclei were stained in blue (DAPI). HUVECs (e) were used as positive control. Scale bars=20 mm. Panel B only showed
the Mean6SEM of CD31 antibody staining in Group 1 (n=5 patients). ***: p,0.001 compared to control (Before c-kit MACS). Panel C confirmed the
above results with different endothelial specific antibody (KDR). The percentages of KDR
+ cells before (f, h) and after (g, i) c-kit MACS in two groups (f
and g in Group 1, h and i in Group 2) were similar to those in CD31 experiments mentioned above. In the images, KDR
+ cells were labeled in red (APC)
and nuclei were stained in blue (DAPI). HUVECs (j) were used as positive control. Scale bars=20 mm. Panel D only showed the Mean6SEM of KDR
antibody staining of Group 1. n=3 patients. *: p,, ***: p,0.001 compared to control (Before c-kit MACS).
doi:10.1371/journal.pone.0027719.g008
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to passage 10. Moreover after c-kit MACS, c-kit
+/Lin
2 cells were
negative for hematopoietic stem cells (CD34, CD45, CD133) and
Lin markers, however, in a few patients cells positive for endothelial
marker (KDR/CD31) were observed. Lin-dep procedure seemed
unnecessary for further enrichment of c-kit
+ cells. No contamination
from fibroblasts and mast cells was found. Importantly, c-kit
+ CSCs
could differentiate into three cardiac lineages. A major of these cells
were transformed into cardiomyocytes, while a small population
differentiated into smooth muscle and endothelial cells. Although
several laboratories have published studies describing the isolation
and characterization of human c-kit
+/Lin
2 CSCs [9,12,22,23,47]
the stability of the stem cell characteristics of the population,
contamination from hematopoietic stem cells or differentiation into
cells of cardiovascular lineage has not been clearly established and
therefore remain controversial [34,45,48].
Stable expression of c-kit in CSCs
Recent evidence supports the view that the adult heart contains
a discrete population of self-renewing stem cells [1,36,49,50].
Using different stem cell markers and isolation methods, at least
five different types of CSCs (c-kit
+/Lin
2; Sca-1
+; Isl1
+, cardiac side
population/Abcg2
+/MDR
+ cells, and cardiospheres/c-kit
+/Sca-
1
+/Flk1
+) have been described [13,21]. Among these, the c-kit
+/
Lin
2 population has been most widely studied. These cells
demonstrate typical stem cell properties of self-renewing, clono-
genesis, and multipotency with the ability to differentiate into
cardiomyocytes, smooth muscle cells, and endothelial cells in vitro
[1]. Although in some in vivo studies c-kit
+/Lin
2 cells have shown
beneficial results against cardiac remodeling after MI, in others no
effect or only marginally significant effects were observed [13,51–
54]. This inconsistency may be related to variations in procedures
used for cell isolation and transplantation and the lack of a
Figure 9. Early cardiac transcription factor staining. Panel A showed the representative Confocal images of GATA4 (upper row, white) and
Nkx2.5 (lower row, red) antibody staining on human c-kit
+ CSCs. Insets in b and e showed the enlarged overlap images of GATA4
+/c-kit
+ and Nkx2.5
+/
c-kit
+ cells, respectively. The secondary antibody (2u AB) conjugated with FITC or APC were used as negative control. c-kit was stained in green (FITC)
and nuclei were stained in blue (DAPI). Scale bars=20 mm. Panel B and C showed the Mean6SEM of GATA4 and Nkx2.5 ICC data from three patients,
respectively, where single positive (c-kit
+) and double positive (c-kit
+/GATA4
+, left panel; c-kit
+/Nkx2.5
+, right panel) cells were counted and
percentages were plotted.
doi:10.1371/journal.pone.0027719.g009
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minimizing contamination by other cells.
In normal human heart, c-kit
+ CSCs reside in discrete stem cell
niches, but their overall abundance in the heart is rather low.
Although some investigators have attempted to quantify the
percentage of c-kit
+ cells in whole heart [1], it is difficult to obtain
accurate estimates based on quantification of heart section or
freshly isolated cells. Quantification of c-kit
+ cells by counting
every single cell (including c-kit
+ cells) in the entire human heart is
tedious and often not feasible. On the other hand, counting these
cells in fresh cell isolates is confounded by the presence of a large
amount of dead cells, cell debris and clumps, making it difficult to
get an accurate estimate of the abundance of the c-kit
+ population
either by flow cytometry or immunestaining. Nevertheless, our
histological analysis of the atrial appendage indicated that the
abundance of these cells in the human hearts is similar to that
reported for the rat heart [12]. Because the right atrium is believed
to be the highest levels of these cells [22,23], it is likely the
percentage of c-kit
+ in other parts of heart might be even lower.
Thus, expansion of c-kit
+ cells from samples of the ventricle or the
septum is likely to be more difficult than from atrial tissue and
would require a longer time to allow the cells to grow to numbers
required for clinical transplantation.
The impact of long-term cell culture on the enrichment of c-kit
+
cells before purification has not been systemically assessed either.
The published data are variable. Itzhaki-Alfia et al found that the
dissociated human right-atrium generated 2462.5% of c-kit
+
before c-kit
+ cell purification [22]., whereas Messina et al have
reported that in cardiospheres-derived stem cells of murine heart
there were ,30% c-kit
+ cells at Day 6 vs 10% at Day 0 after
platting [9]; where Davis et al demonstrated that in rat heart, there
were ,12% c-kit
+ cells on Day 21 vs 5% at Day 7 after culture
[55]. We found that c-kit
+ cells were gradually increased from very
lower level in freshly isolated preparation up to 10% to 40%
within two passage (about ten days) before c-kit MACS procedure.
During the long-term culture (about 40–50 days), the percentage
of c-kit
+ cells remained stable at about 30–40% without any
purification processes. The underlying mechanisms for this
increase in c-kit
+ cells remain unknown, but the expansion of
these cells probably depends upon natural selection exerted by
culture medium, which may favor or facilitate the proliferation of
c-kit
+ CSCs over other cell types [9,56–58]. However despite of
such selection, the abundance of c-kit
+ cells did not exceed 80%
unless c-kit MACS step was applied. Following this procedure, the
purified c-kit
+ cell population were be able to maintain its c-kit
expression at a high level for more than month thus providing a
uniform and stable population appropriate for clinical use.
Contaminations of other cells types
Following the initial study reporting c-kit
+ CSCs in the rat heart
[1], several investigators have identified CSCs from hearts of
various species, including mice [9,59], rats [60], dogs [61], pigs
[62], and humans [12,36]. These studies were focused mainly on
c-kit
+/Lin
2 cells populations, with little consideration of contam-
ination from other cell types such as the mast cells, which are also
c-kit
+. In addition to CSCs, the c-kit antigen also expressed on
other tissues including hematopoietic stem cells from the bone
marrow [63,64], cardiac mast cells [33,34], melanocytes [65],
Figure 10. Cardiac lineage differentiation induced by 5-azacytidine. Panel A displayed the representative RT-PCR data of cardiac lineage
genes (cardiac genes: GATA4, MEF2c, cTnI, and MLC2v; endothelial genes: KDR and vWF) before (Day 0) and after differentiation (Day 3, 7, 14, 21, 28,
and 35). Stem cell marker (c-kit) and GAPDH were also included as a control. Total RNA of human Jurkat cell (J), human Heart (H) and human carotid
artery (A) were used as negative and positive controls, respectively. DNA molecular marker (M) was shown the first column as M (bp). Panel B showed
the representative Confocal images of c-kit (green-FITC), CD31 (red-APC), a-SMA (green-FITC), a-SA (red-APC), and cTnI (red-APC) before (upper) and
after (lower) differentiation. Nuclei were stained in blue (DAPI). Scale bars=20 mm. Panel C showed the MEAN6SEM of quantitative ICC data from
three patients (n=3 patients). *: p,0.05, **: p,:0.01, ***: p,0.001. Each data was compared with its control levels (before differentiation).
doi:10.1371/journal.pone.0027719.g010
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Indeed within the population of cells isolated from the atrial
appendage using enzymatic dissociation, we did find small
percents of contaminating cell population expressing Lin, the
fibroblast antigen, KDR or CD31. Although most of contaminat-
ed cells could be excluded using c-kit MACS, but in many cases
the purity of c-kit
+ could not reach 100%, suggesting that other
un-identified cell types, not identified by current approaches and
cellular markers, may be present in the preparation. Nevertheless,
we confirmed that a majority (.80%) of sorted CSCs were c-kit
+
and the rest of contaminated cells (if any) are not mast cell,
fibroblasts, hematopoietic stem cells, and/or lineage cells. These
data are consistent with other published studies [1,12,13,
23,36,47]. However, Zhou et al have recently reported that 85%
to 100% c-kit
+ cells isolated from human left ventricle were mast
cells that displayed a weak or moderate signal for CD45, but were
strongly positive for mast-cell markers such as Tryptase, Toluidine
blue and Thionine [34]. In contrast, we found that c-kit
+ cells were
negative for mast cell marker even before c-kit purification and
that these cells were also CD45 negative (as confirmed by flow
cytometry and ICC using cells from at least three different
patients). This disparity may be due to several reasons including
the use of different experimental conditions, methods, patient, and
especially tissue used to isolate the cells. For instance, Zhou used
biopsy from left ventricle tissues v.s. the atrial appendages used in
the present study. Another potential reason for undetectable mast
cells in the present study may be due to non-adherent property of
mast cells, which were probably washed away when medium was
changed next day. It is known that the optimal methods are critical
for the successful identification of true cardiac mast cells [68],
hence the use of culture conditions described here should preclude
contamination from mast cells and facilitate high yield recovery of
a uniform population of c-kit
+ CSCs.
Cardiac differentiation potential
A variety of CSCs isolated from humans and experimental
models [13] have been differentiated into cardiovascular lineages
using different culture condition, including co-culture with mature
or neonatal cardiomyocytes [5,8,69,70], induction with 5-azacy-
tidine [4], Oxytocin [3], or Dexamethasone [1,12,36]. Although
these c-kit
+/Lin
2 CSCs have been widely studied, attempts to
differentiate these cells in vitro have led to inconsistent results. It
has been previously reported that in intact tissues sections from
human hearts, the percentage of c-kit
+ cells in right atrial tissue
decreases from 8.960.4% in neonates to 6.460.2% to 3.260.1%
in children from 2 to 13 years. Resident CSCs have been found to
be most abundant in hearts of neonates [23]. However in adult
human heart, the number of c-kit
+ cells in even lower 0.01% [12],
which was comparable to our estimates presented here. Because c-
kit
+/Lin
2 cells are pre-committed resident CSCs, it is likely that
they exist in heart in various stages of development and therefore
they express cardiac lineage markers. Published data support this
hypothesis. In human heart during early development c-kit
+ and
Nkx2.5
+ were co-expressed in some CSCs with relative lower
levels that range from 2.960.1% in neonates, 1.560.1% in infants
to 1.060.1% in children 2 to 13 years [23]. In adult hearts,
however, several different populations of stem cells committed to
the cardiac lineage have been identified. These include (a) pre-
committed cardiomyocytes co-expressing c-kit
+/Nkx2.5
+, c-kit
+/
a-SA
+, c-kit
+/a-SA
+/Nkx2.5
+, c-kit
+/MEF2c
+, c-kit
+/a-SA
+/
MEF2c
+ in CSC niches of tissue sections of rat [1], mouse [71],
and human hearts [12,72]; (b) Pre-committed endothelial
progenitors co-expressing c-kit
+/vWF
+, c-kit
+/KDR
+, c-kit
+/
vWF
+/KDR
+; and (c) Pre-committed smooth muscle cells co-
expressing c-kit
+/KDR
+/a-SMA
+ in vascular niches of human
hearts [1,12,72]. However, due to a variety of technical reasons,
the actual number of each type of pre-committed CSCs within the
entire heart has not been reported [12], although their abundance
has been presumed to be low. Nevertheless, previous published
data as well as our present data suggests that several types of pre-
committed CSCs at various differentiation stages exist in adult
hearts and therefore it is possible to obtain or identify these cells
after dissociation.
In vitro single cell preparations of cardiac cells provide an
alternative approach for identifying pre-committed CSCs with
specific antibodies including anti-c-kit and/or other cardiac
lineage markers or by using the more sensitive RT-PCR technique
to detect cardiac genes expression. Previous studies from several
laboratories have reported variable levels of c-kit
+ expressions in
cultured cells before purification and differentiation. Beltrami et al
[1] found that the percentage of c-kit
+ cell was 7–10% in cells
isolated from the rat heart; but in cells isolated from the adult
human right atrium, nearly 20 to 40% of the cells [12] [22] were
found to be c-kit
+. This estimate is similar to our finding that 10–
40% of the cells in isolate were c-kit
+ before purification and
differentiation. Characterization of early myogenic transcription
factors of CSCs isolated from human heart has shown that
6066% [22] or 59614% [12] of the cells were GATA4
+ whereas
60611% [22] of the cells were also positive for the late cardiac
marker (a-SA). In agreement with these results we found that
nearly 50% of cells were positive for both c-kit and GATA4.
However, the abundance of c-kit
+ cells expressing Nkx2.5, a-
SMA, and a-SA was low. Based on cardiac lineage makers and
their capacity for differentiation, D’Amario et al have suggested
that c-kit
+ CSCs could be classified into two groups - the
‘‘myogenic CSCs’’ (mCSCs) and the ‘‘vasculogenic CSCs’’
(vCSCs) [36]. This classification was based on their data showing
that most of the mCSCs became cardiomyocytes, whereas the
vCSCs differentiate primarily into endothelial and smooth muscle
cells [36]. However, in their study, before differentiation, the c-kit
+
cell population was negative for the cardiovascular markers -
GATA4, Nkx2.5, MEF2c, a-SA, a-SMA, CD31, and TGF-b-1R
and only a small percent of cells (3.361.1%) were positive for
KDR, as determined by flow cytometry [12,36,72]. This is
inconsistent with the previous study using the same technique [12]
or the results obtained by other investigators [22,23] including our
data presented here. Hence, the extent of differentiation of human
CSCs in situ or before in vitro differentiation remains unclear.
Cardiac lineage differentiation of c-kit
+/Lin
2 cells have been
studied in various laboratories using either chemical reagents (such
as Dexamethasone) or co-culture with neonatal or matured
cardiomyocytes [13]. It has been reported that treatment with
Dexamethasone results in the appearance of cardiac markers
GATA4, Nkx2.5, MEF2c, and cardiac a-SA) in ,50% of mCSCs,
whereas ,10–15% of the cells show smooth muscle and
endothelial markers (GATA6, a-SMA, CD31, and vWF) after
differentiation [36]. On the other hand, ,40%–50% vCSCs
became positive for smooth muscle and endothelial markers
(GATA6, a-SMA, CD31, and vWF), and small percents of them
(,10–15%) showed positive for cardiac markers (GATA4, Nkx2.5,
MEF2c, and a-SA) after differentiation [36]. In our study upon
treatment with 5-AZ [37], we observed that a majority (,70%) of
c-kit
+ cells differentiated into cardiomyocytes, but small percent
(,30%) of c-kit
+ cells became smooth muscle and endothelial cells,
demonstrating more efficient cardiomyocyte differentiation has
been reported than before [36].
In conclusion, we have systemically and quantitatively charac-
terized c-kit
+/Lin
2 CSCs isolated from human atrial appendages.
Human Cardiac Stem Cells Stably Express c-kit
PLoS ONE | www.plosone.org 13 November 2011 | Volume 6 | Issue 11 | e27719We have developed appropriate procedures and protocols for
maintaining purified c-kit
+ cells. The cells maintained in culture
stably expressed high percentage of c-kit antigen without
contamination by other cells types except for in a few cases by
CD31
+ and KDR
+ cells. Upon induction of differentiation, CSCs
were able to become cardiomyocytes, smooth muscle and
endothelial cells. We conclude that by using the simplified
enzymatic dissociation method, a large number, but higher
percent of relative pure c-kit
+/Lin
2 CSCs could be obtained
from atrial appendages specimens within ,4 weeks following c-kit
MACS without Lin-dep. This simple, but cost-effective approach
could be used to obtain sufficient numbers of stable c-kit
+ cells for
transplantation into patients with heart failure and myocardial
infarct.
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